Genetic Leap, an AI and RNA genetic-medicine company, is partnering with Eli Lilly to develop genetic medicine therapeutics using their RNA-targeted AI platform. The collaboration aims to produce oligonucleotide drugs for crucial therapeutic areas chosen by Lilly. Lilly will provide Genetic Leap with $409 million in upfront payments and royalties. RNA plays a key role in biological processes, and RNA medicines have potential in treating diseases that traditional drugs cannot. Other companies, like Deep Genomics, are also using AI technology for RNA therapeutics. Genetic Leap previously partnered with Astellas Pharma to develop RNA-targeted small molecule therapeutic candidates against an oncology target.
Source link
Genetic Leap, Lilly partner to expedite genetic medicine development with AI
